Through the Inflation Reduction Act, the Centers for Medicare & Medicaid Services (CMS) is implementing drug price negotiation to lower prescription drug costs for people with Medicare and reduce drug spending by the federal government.
With a 20-year history supporting CMS with such complex legislative changes as the Affordable Care Act, Medicare Access and CHIP Reauthorization Act, and Medicare Modernization Act, Guidehouse is a trusted partner with supporting policy decisions and promoting innovation. We also bring relevant experience across the health ecosystem, from Food and Drug Administration drug development to federal and commercial pharmacy operations and regulatory compliance. Our integrated public and commercial sector strategy, change management, IT and analytics, clinical, and program transformation experts help federal health agencies achieve their missions and sustainable success.
Read more about Considerations for Implementing Drug Price Negotiation.Unintended Consequences
It is important to consider risks and unintended consequences associated with developing and operationalizing policies and procedures and establishing monitoring and reporting processes. Some specific considerations for drug price negotiation include:
For reference: CMS Implementation Timeline
Learn more about our drug pricing and reimbursement expertise: